[go: up one dir, main page]

WO2005116250A8 - Viral and viral associated mirnas and uses thereof - Google Patents

Viral and viral associated mirnas and uses thereof

Info

Publication number
WO2005116250A8
WO2005116250A8 PCT/IB2005/002352 IB2005002352W WO2005116250A8 WO 2005116250 A8 WO2005116250 A8 WO 2005116250A8 IB 2005002352 W IB2005002352 W IB 2005002352W WO 2005116250 A8 WO2005116250 A8 WO 2005116250A8
Authority
WO
WIPO (PCT)
Prior art keywords
viral
associated mirnas
mirnas
viral infections
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2005/002352
Other languages
French (fr)
Other versions
WO2005116250A2 (en
WO2005116250A3 (en
Inventor
Itzhak Bentwich
Amir Avniel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rosetta Genomics Ltd
Original Assignee
Rosetta Genomics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/709,739 external-priority patent/US7777022B2/en
Application filed by Rosetta Genomics Ltd filed Critical Rosetta Genomics Ltd
Priority to EP05774516A priority Critical patent/EP1751311A2/en
Priority to CA002567937A priority patent/CA2567937A1/en
Priority to JP2007514216A priority patent/JP2008500039A/en
Priority to AU2005248149A priority patent/AU2005248149A1/en
Publication of WO2005116250A2 publication Critical patent/WO2005116250A2/en
Publication of WO2005116250A3 publication Critical patent/WO2005116250A3/en
Priority to US11/511,035 priority patent/US7795419B2/en
Priority to IL179545A priority patent/IL179545A/en
Anticipated expiration legal-status Critical
Publication of WO2005116250A8 publication Critical patent/WO2005116250A8/en
Priority to US12/850,091 priority patent/US8455633B2/en
Priority to US14/797,381 priority patent/US9624556B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/10—Production naturally occurring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16221—Viruses as such, e.g. new isolates, mutants or their genomic sequences

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

Described herein are novel polynucleotides associated with viral infections. The polynucleotides are miRNAs and miRNA precursors. Related methods and compositions that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of viral infections.
PCT/IB2005/002352 2004-05-26 2005-05-26 Viral and viral associated mirnas and uses thereof Ceased WO2005116250A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
EP05774516A EP1751311A2 (en) 2004-05-26 2005-05-26 Viral and viral associated mirnas and uses thereof
CA002567937A CA2567937A1 (en) 2004-05-26 2005-05-26 Viral and viral associated mirnas and uses thereof
JP2007514216A JP2008500039A (en) 2004-05-26 2005-05-26 Viral miRNA and virus-related miRNA and uses thereof
AU2005248149A AU2005248149A1 (en) 2004-05-26 2005-05-26 Viral and viral associated miRNAs and uses thereof
US11/511,035 US7795419B2 (en) 2004-05-26 2006-08-28 Viral and viral associated miRNAs and uses thereof
IL179545A IL179545A (en) 2004-05-26 2006-11-23 Viral and viral associated mirnas and uses thereof
US12/850,091 US8455633B2 (en) 2004-05-26 2010-08-04 Viral and viral associated mirnas and uses thereof
US14/797,381 US9624556B2 (en) 2004-05-26 2015-07-13 Viral and viral associated miRNAs and uses thereof

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US10/709,739 US7777022B2 (en) 2002-12-05 2004-05-26 Bioinformatically detectable group of novel regulatory viral and viral associated oligonucleotides and uses thereof
US10/709,739 2004-05-26
US52245104P 2004-10-03 2004-10-03
US52245004P 2004-10-03 2004-10-03
US60/522,451 2004-10-03
US60/522,450 2004-10-03
US52245904P 2004-10-04 2004-10-04
US60/522,459 2004-10-04
US66509405P 2005-03-25 2005-03-25
US60/665,094 2005-03-25

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/709,739 Continuation-In-Part US7777022B2 (en) 2002-12-05 2004-05-26 Bioinformatically detectable group of novel regulatory viral and viral associated oligonucleotides and uses thereof

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/511,035 Continuation US7795419B2 (en) 2004-05-26 2006-08-28 Viral and viral associated miRNAs and uses thereof
US11/511,035 Continuation-In-Part US7795419B2 (en) 2004-05-26 2006-08-28 Viral and viral associated miRNAs and uses thereof

Publications (3)

Publication Number Publication Date
WO2005116250A2 WO2005116250A2 (en) 2005-12-08
WO2005116250A3 WO2005116250A3 (en) 2006-07-06
WO2005116250A8 true WO2005116250A8 (en) 2007-07-05

Family

ID=42331989

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/002352 Ceased WO2005116250A2 (en) 2004-05-26 2005-05-26 Viral and viral associated mirnas and uses thereof

Country Status (7)

Country Link
EP (1) EP1751311A2 (en)
JP (1) JP2008500039A (en)
CN (1) CN101031658A (en)
AU (1) AU2005248149A1 (en)
CA (1) CA2567937A1 (en)
IL (1) IL179545A (en)
WO (1) WO2005116250A2 (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040219565A1 (en) 2002-10-21 2004-11-04 Sakari Kauppinen Oligonucleotides useful for detecting and analyzing nucleic acids of interest
US8071306B2 (en) 2005-01-25 2011-12-06 Merck Sharp & Dohme Corp. Methods for quantitating small RNA molecules
EP1851336B1 (en) * 2005-01-25 2010-09-08 Rosetta Inpharmatics LLC Methods for quantitating small rna molecules
CA2610702A1 (en) * 2005-06-03 2006-12-07 Michael Zenon Michael Targeting cells with altered microrna expression
CN101421421A (en) * 2006-03-31 2009-04-29 利琴蒂亚有限公司 Method and microarray for detecting herpesviruses
US8007790B2 (en) 2006-04-03 2011-08-30 Stowers Institute For Medical Research Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases
US7727725B2 (en) 2006-04-27 2010-06-01 Celera Corporation Genetic polymorphisms associated with liver fibrosis, methods of detection and uses thereof
EP2038432B1 (en) * 2006-06-30 2017-02-08 Rosetta Genomics Ltd Method for detecting and quantifying a target nucleic acid generated by rt-pcr of mirna
US8227590B2 (en) 2006-11-21 2012-07-24 Jawaharlal Nehru Centre For Advanced Scientific Research High sensitivity assay for molecular typing of biological sample, probes and a kit thereof
SG143090A1 (en) * 2006-11-27 2008-06-27 Agency Science Tech & Res Influenza b virus detection method and kit therefor
WO2009024834A2 (en) * 2006-12-05 2009-02-26 Rosetta Genomics Ltd Nucleic acids involved in viral infection
WO2010083464A2 (en) * 2009-01-16 2010-07-22 Cepheid Methods of detecting cervical cancer
US20100240049A1 (en) 2009-01-16 2010-09-23 Cepheid Methods of Detecting Cervical Cancer
WO2011088226A2 (en) 2010-01-13 2011-07-21 Caris Life Sciences Luxembourg Holdings Detection of gastrointestinal disorders
JP5926194B2 (en) * 2010-01-18 2016-05-25 ユニベルシテイト ユトレヒト ホールディング ビー．ブイ． Means and method for distinguishing between FECV and FIPV
AU2011223789A1 (en) 2010-03-01 2012-09-20 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
US9469876B2 (en) 2010-04-06 2016-10-18 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers for metastatic prostate cancer
WO2012047956A2 (en) 2010-10-06 2012-04-12 Opko Curna Llc Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4
EP3533873A1 (en) 2011-09-14 2019-09-04 Translate Bio MA, Inc. Multimeric oligonucleotide compounds
CA2868812A1 (en) * 2012-03-30 2013-10-03 Intelligent Medical Devices, Inc. Optimized probes and primers and methods of using same for the binding, detection, differentiation, isolation and sequencing of herpes simplex virus
AU2013205110B2 (en) 2012-04-24 2016-10-13 Gen-Probe Incorporated Compositions, Methods and Kits to Detect Herpes Simplex Virus Nucleic Acids
WO2015191583A2 (en) 2014-06-09 2015-12-17 Biomed Valley Discoveries, Inc. Combination therapies targeting tumor-associated stroma or tumor cells and topoisomerase
US10434174B2 (en) 2014-06-09 2019-10-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination therapies using platinum agents and agents that target tumor-associated stroma or tumor cells
WO2015191568A2 (en) 2014-06-09 2015-12-17 Biomed Valley Discoveries, Inc. Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature
WO2015191590A2 (en) 2014-06-09 2015-12-17 Biomed Valley Discoveries, Inc. Combination therapies targeting tumor-associated stroma or tumor cells and microtubules
WO2015191617A2 (en) 2014-06-09 2015-12-17 Biomed Valley Discoveries, Inc. Combination therapies using anti-metabolites and agents that target tumor-associated stroma or tumor cells
US10758526B2 (en) 2014-06-09 2020-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services National Institutes Of Health Combination therapies using agents that target tumor-associated stroma or tumor cells and other pathways
US10556020B2 (en) 2014-09-26 2020-02-11 University Of Massachusetts RNA-modulating agents
WO2016130943A1 (en) * 2015-02-13 2016-08-18 Rana Therapeutics, Inc. Hybrid oligonucleotides and uses thereof
JP6786529B2 (en) 2015-06-29 2020-11-18 バイオメッド バレー ディスカバリーズ，インコーポレイティド Combination of LPT-723 and Immune Checkpoint Inhibitors and Methods of Treatment
US20190038771A1 (en) * 2016-02-02 2019-02-07 Crispr Therapeutics Ag Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
AU2017277647B2 (en) 2016-06-08 2023-07-27 President And Fellows Of Harvard College Engineered viral vector reduces induction of inflammatory and immune responses
WO2017217935A1 (en) * 2016-06-14 2017-12-21 Agency For Science, Technology And Research Use of mi r-198 in treating and diagnosing cutaneous squamous cell carcinoma
SG11202000523PA (en) 2017-07-31 2020-02-27 The Trustees Of Columbia Univeristy In The City Of New York Compounds, compositions, and methods for treating t-cell acute lymphoblastic leukemia
KR20200085812A (en) 2017-11-08 2020-07-15 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Compositions and methods for inhibiting viral vector-induced inflammatory response
AU2019258585A1 (en) * 2018-04-23 2020-11-26 BiomeMega Pty Ltd A microbial sanitiser with broad applications
WO2020027227A1 (en) * 2018-07-31 2020-02-06 国立大学法人大阪大学 Small cell lung cancer therapeutic agent containing oligonucleotide
CA3105385A1 (en) * 2018-09-18 2020-03-26 Alnylam Pharmaceuticals, Inc. Ketohexokinase (khk) irna compositions and methods of use thereof
IL294860A (en) * 2020-01-31 2022-09-01 Paros Bio Inc Gene therapy for neurodegenerative disorders using polynucleotide silencing and replacement (Hebrew)
KR20230150844A (en) 2021-02-26 2023-10-31 알닐람 파마슈티칼스 인코포레이티드 Ketohexokinase (KHK) iRNA compositions and methods of using the same
KR102644654B1 (en) 2021-04-19 2024-03-07 노보 노르디스크 에이/에스 Compositions and methods for inhibiting nuclear receptor subfamily 1 group H member 3 (NR1H3) expression
DE112022004237T5 (en) * 2021-09-03 2024-07-04 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung eingetragener Verein DNA aptamers and their use in the (pre-)diagnosis of cancer
US11898186B1 (en) 2022-08-10 2024-02-13 Genscript Usa Inc. Compositions and methods for preparing capped mRNA

Also Published As

Publication number Publication date
EP1751311A2 (en) 2007-02-14
JP2008500039A (en) 2008-01-10
WO2005116250A2 (en) 2005-12-08
CN101031658A (en) 2007-09-05
WO2005116250A3 (en) 2006-07-06
AU2005248149A1 (en) 2005-12-08
IL179545A0 (en) 2007-05-15
CA2567937A1 (en) 2005-12-08
IL179545A (en) 2010-12-30

Similar Documents

Publication Publication Date Title
WO2005116250A8 (en) Viral and viral associated mirnas and uses thereof
WO2005111211A8 (en) Micronas and uses thereof
WO2009108866A3 (en) Microrna signatures associated with cytogenetics and prognosis in acute myeloid leukemia (aml) and uses thereof
WO2007148235A3 (en) Cancer-related nucleic acids
WO2010018563A3 (en) Compositions and methods for the prognosis of lymphoma
WO2009105513A3 (en) Novel compounds and methods for therapy
AU2008298744A8 (en) MiRNA expression in human peripheral blood microvesicles and uses thereof
WO2008127364A3 (en) Antiviral compounds and use thereof
WO2008115281A3 (en) Compounds for treating viral infections
WO2008066784A3 (en) Expression of foxp3 by cancer cells
WO2008027600A3 (en) Imatinib compositions
WO2009120712A3 (en) Compositions and methods for diagnosing and treating melanoma
WO2011130426A3 (en) Compositions and methods for treatment of melanoma
WO2008092099A8 (en) Compositions and methods for treating hematopoietic malignancies
WO2011021177A3 (en) Compositions and methods for prognosis and treatment of prostate cancer
WO2009098464A3 (en) Use of g-rich oligonucleotides for treating neoplastic diseases
EP2325333A8 (en) MicrorRNAs and uses thereof
WO2009147658A3 (en) Compositions and methods for diagnosis, prognosis and treatment of mesothelioma
WO2006091861A8 (en) Compositions and methods relating to cns lymphoma
WO2010058393A3 (en) Compositions and methods for the prognosis of colon cancer
WO2007062380A3 (en) Modulation of eif4e-bp2 expression
WO2012014190A3 (en) Compositions and methods for prognosis of mesothelioma
WO2008085927A3 (en) Methods, compositions, and kits for the treatment of pain
WO2009105507A3 (en) Beloxepin, its enantiomers, and analogs thereof for the treatment of pain
WO2011039757A3 (en) Compositions and methods for prognosis of renal cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 11511035

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2567937

Country of ref document: CA

Ref document number: 179545

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2007514216

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2005248149

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 7427/DELNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2005774516

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2005248149

Country of ref document: AU

Date of ref document: 20050526

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 11511035

Country of ref document: US

Ref document number: 2005248149

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200580025300.4

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005774516

Country of ref document: EP